Resources Archive - Page 9 of 48

Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...

HPV18-Related Cancer Model Development

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV...

Development of Novel ADC-Resistant Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

DNA-Compatible Huisgen Cycloaddition

In our latest publication, WuXi AppTec scientists introduce two new methods that utilize readily accessible aldehydes to create substituted isoxazolines...

AACR 2025 Posters: Sneak Peek

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...

Poster Presentations at AACR 2025

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present...

Advancements in Membranous Nephropathy

From Pathogenesis to Therapeutic Innovations Introduction: Membranous nephropathy (MN) has received particular attention among autoimmune kidney disease due to its...

Sclerosis and Fibrosis Disease Models

Systemic sclerosis (also known as scleroderma) is a chronic autoimmune disease that leads to the buildup of scar tissue in...

Synthetic Lethality Related Tumor Models

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like...

Knowledge Library